New York, United States
Lifebit, founded in 2017, has positioned itself at the forefront of federated health data infrastructure, leveraging a specialized platform that permits extensive analysis of sensitive biomedical data without relocating it from its source. This innovation aligns with the critical need for secure data handling, emphasized by the implementation of the ONS Five Safes framework. This system maintains data sovereignty and mandates rigorous output verification through an "airlock" process.
Lifebit has successfully powered high-profile projects, including Genomics England and other leading biobanks, demonstrating its validity in supporting large-scale genomics and cross-border biomedical AI without undermining patient trust. By addressing needs in the AI, Biotechnology, Cloud Infrastructure, and Life Sciences sectors, the company appeals significantly to pharma companies, biobanks, and government entities.
Currently headquartered in the United States, Lifebit secured a substantial $60.00M Series B investment on 01 September 2021 from major investors including Beacon Capital, Pentech Ventures, Tiger Global, and Eurazeo, underscoring strong investor confidence in their scalable, secure, and innovative solutions.
